Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Haemophilus influenzae type b Capsular Polysaccharide Antigen (Conjugated) (Hib PRP Conjugate)
- Target
- Hib PRP Conjugate
- Molecular classification
- Polysaccharide, Conjugate vaccine component, Antigen
01
Overview
The Haemophilus influenzae type b (Hib) capsular polysaccharide antigen, specifically polyribosylribitol phosphate (PRP), when conjugated to a carrier protein like tetanus toxoid, diphtheria toxoid, CRM197, or Neisseria meningitidis OMP, forms the active component of Hib conjugate vaccines. These vaccines stimulate a T-dependent immune response, leading to long-lasting immunity against invasive Hib diseases in infants and young children.
- Other names
- Polyribosylribitol phosphate (PRP)Hib capsular polysaccharideHib conjugate vaccine antigenActHIBPedvaxHIBHiberixComvax
02
Mechanism of action
Conjugation of PRP to a carrier protein (Tetanus toxoid, Diphtheria toxoid, CRM197, or Neisseria meningitidis OMP) enhances immunogenicity by converting a T-independent antigen into a T-dependent antigen, leading to robust B and T cell activation, class switching to IgG, affinity maturation, memory B cell formation, and long-lasting immunity.
03
Biological functions
Antigenic stimulationInduction of humoral immunityB cell activationT cell activation
04
Disease associations
Prevention of Haemophilus influenzae type b infectionsPrevention of meningitisPrevention of epiglottitisPrevention of pneumoniaPrevention of pericarditisPrevention of septic arthritis
05
Safety considerations
Mild pain at injection siteLow-grade feverRare severe adverse reactions
06
Interacting drugs
ActHIB
3 more in the full profile.
07
Biomarkers
Anti-PRP antibody titers
Beyond the preview
Go deeper on Haemophilus influenzae type b Capsular Polysaccharide Antigen (Conjugated) (Hib PRP Conjugate).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haemophilus influenzae type b Capsular Polysaccharide Antigen (Conjugated) (Hib PRP Conjugate).